TB-500 (5mg Vial) & BPC-157 (5mg Vial) Dosage Protocol

TB-500 + BPC-157 Stack (5 mg Vials) Dosage Protocol

Quickstart Highlights

TB-500 (Thymosin β4) is a 43-amino-acid peptide that promotes tissue repair and regeneration through enhanced angiogenesis and cellular migration[1][2]. BPC-157 (Body Protection Compound-157) is a 15-amino-acid gastric peptide studied for accelerating musculoskeletal healing by upregulating growth factor signaling[3][4]. Stacking these peptides is a common research approach for synergistic tissue repair support.

  • TB-500 Reconstitution: Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration.
  • BPC-157 Reconstitution: Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration.
  • TB-500 Dosing: 1,250 mcg (50 units) twice weekly (Weeks 1–4), then once weekly (Weeks 5–12).
  • BPC-157 Dosing: 250–500 mcg (10–20 units) daily, titrated over 12 weeks.
  • Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL = 25 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); after reconstitution, refrigerate and use within ~30 days.

Dosing & Reconstitution Guide

Educational guide for reconstitution and combined dosing protocol

TB-500 Protocol (2 mL Reconstitution = 2.5 mg/mL)

Week Dose (mcg) Units (per injection) (mL) Frequency
Weeks 1–4 1,250 mcg (1.25 mg) 50 units (0.50 mL) Twice weekly
Weeks 5–12 1,250 mcg (1.25 mg) 50 units (0.50 mL) Once weekly

Route: Subcutaneous injection. The loading phase (Weeks 1–4) uses twice-weekly dosing to establish tissue saturation, followed by a maintenance phase (Weeks 5–12) at once weekly[1].

TB-500 Reconstitution Steps

  1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

BPC-157 Protocol (2 mL Reconstitution = 2.5 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL) Frequency
Weeks 1–2 250 mcg (0.25 mg) 10 units (0.10 mL) Once daily
Weeks 3–8 500 mcg (0.50 mg) 20 units (0.20 mL) Once daily
Weeks 9–12 250 mcg (0.25 mg) 10 units (0.10 mL) Once daily

Route: Subcutaneous injection, preferably near the site of injury. Preclinical research commonly uses 250–500 mcg per day for musculoskeletal applications[3][4]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

BPC-157 Reconstitution Steps

  1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week combined protocol with the schedules above.

  • TB-500 Vials (5 mg each):

    • 8 weeks ≈ 3 vials
    • 12 weeks ≈ 4 vials
    • 16 weeks ≈ 5 vials
  • BPC-157 Vials (5 mg each):

    • 8 weeks ≈ 5 vials
    • 12 weeks ≈ 7 vials
    • 16 weeks ≈ 8 vials
  • Insulin Syringes (U-100):

    • 8 weeks: 68 syringes (TB-500: 12 + BPC-157: 56)
    • 12 weeks: 100 syringes (TB-500: 16 + BPC-157: 84)
    • 16 weeks: 132 syringes (TB-500: 20 + BPC-157: 112)
  • Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.

    • 8 weeks (8 total vials): 16 mL → 2 × 10 mL bottles
    • 12 weeks (11 total vials): 22 mL → 3 × 10 mL bottles
    • 16 weeks (13 total vials): 26 mL → 3 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each administration.

    • 8 weeks: ~160 swabs → recommend 2 × 100-count boxes
    • 12 weeks: ~232 swabs → recommend 3 × 100-count boxes
    • 16 weeks: ~304 swabs → recommend 4 × 100-count boxes
TB-500 5mg Vial
View TB-500
BPC-157 5mg Vial
View BPC-157
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

Concise summary of the combined regimen.

  • Goal: Support tissue repair, reduce inflammation, and accelerate recovery from musculoskeletal injuries[1][3].
  • Schedule: TB-500 twice weekly (loading) then once weekly (maintenance); BPC-157 daily throughout.
  • Dose Range: TB-500: 1,250 mcg per injection; BPC-157: 250–500 mcg daily.
  • Reconstitution: 2.0 mL per 5 mg vial for both peptides (~2.5 mg/mL).
  • Storage: Refrigerate lyophilized and reconstituted solutions; use within ~30 days after reconstitution.

Dosing Protocol

Suggested combined approach for synergistic tissue support.

  • TB-500 Loading: 1,250 mcg twice weekly for 4 weeks (total ~2.5 mg/week).
  • TB-500 Maintenance: 1,250 mcg once weekly for Weeks 5–12.
  • BPC-157 Start: 250 mcg daily for 2 weeks, then increase to 500 mcg daily.
  • BPC-157 Taper: Return to 250 mcg daily for final 4 weeks (Weeks 9–12).
  • Timing: Inject at consistent times; BPC-157 preferably near injury site.

Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at 2–8 °C (35.6–46.4 °F); for long-term storage, −20 °C (−4 °F) is acceptable[9].
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~30 days; avoid freeze–thaw cycles.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each injection; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) for TB-500; inject BPC-157 near the target tissue when possible[6].
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose, injection site, and any observations to maintain consistency.
  • Both peptides may be administered on the same day but at different injection sites.

How This Works

TB-500 mimics endogenous thymosin β4, modulating inflammation and activating repair pathways including PI3K/Akt and Notch signaling to enhance angiogenesis and cell migration[1][2]. It promotes actin sequestration and is studied for accelerating wound healing, reducing fibrosis, and improving function after ischemic or traumatic injuries.

BPC-157 upregulates angiogenic pathways (including VEGF) and counteracts inflammatory cytokines[3]. Preclinical research demonstrates improved healing of muscle, tendon, ligament, and bone with no observed toxicity[4][5]. The combination targets complementary mechanisms: TB-500 for systemic tissue repair signaling and BPC-157 for localized healing support.

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

  • TB-500: Preclinical studies show accelerated wound closure, reduced fibrosis, and improved function after ischemic or traumatic injuries[1][2].
  • BPC-157: Preclinical models demonstrate accelerated recovery of tendon, ligament, muscle, and bone injuries with no observed toxicity[3][4]. One clinical series found pain relief in 7 of 12 patients after a single intraarticular knee injection[4].
  • Stack Rationale: The combination may offer complementary mechanisms—systemic repair signaling (TB-500) plus localized tissue healing (BPC-157).
  • Side Effects: Generally well tolerated in research settings; occasional mild injection-site reactions (redness, itching) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

  • Prioritize adequate protein intake to support tissue repair and regeneration.
  • Incorporate appropriate physical therapy or mobility work as tolerated during recovery.
  • Prioritize sleep and stress management to optimize healing responses.
  • Stay hydrated and maintain balanced nutrition to support anabolic processes.

Injection Technique

General subcutaneous guidance from clinical best-practice resources[7][8].

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[8].
  • For BPC-157, injecting near the injury site may enhance local effects[4].

Important Note

This content is for educational purposes only and is not medical advice.

References


  • Frontiers in Endocrinology (2021)
    — Progress on the Function and Application of Thymosin β4
    View Source

  • Annals of the New York Academy of Sciences
    — Thymosin β4: roles in development, repair, and engineering of the cardiovascular system
    View Source

  • Frontiers in Pharmacology (2022)
    — Pharmacokinetics, distribution, metabolism, and excretion of BPC-157
    View Source

  • HSS Journal (2025)
    — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
    View Source

  • Current Pharmaceutical Design (2018)
    — Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract
    View Source

  • Journal of Orthopaedic Surgery and Research (2019)
    — BPC 157 and its effects on tendon healing
    View Source

  • CDC (2024)
    — Vaccine Administration: Subcutaneous (SUBCUT) Injection
    View Source

  • NCBI Bookshelf (2023)
    — Administration of Parenteral Medications – Nursing Skills
    View Source

  • CDC (NCHS)
    — Laboratory Procedure Manual: C-Peptide in Serum (storage guidelines)
    View Source

  • CDC (2023)
    — General Best Practice Guidelines for Immunization: Vaccine Administration
    View Source

  • Pure Lab Peptides
    — TB-500 (5 mg) product page
    View Source

  • Pure Lab Peptides
    — BPC-157 (5 mg) product page
    View Source